Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Healthcare Reporter.
Press releases published on July 31, 2025
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
GlobeNewswire
·
July 31, 2025
MELBOURNE, Australia, July 31, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) announced, in response to recent questions it received from a number of its stockholders, that it does not presently intend to use …
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
GlobeNewswire
·
July 31, 2025
BENGALURU, India, July 31, 2025 (GLOBE NEWSWIRE) -- VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform, cutting drug discovery timelines in half, alongside a strategic …
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
GlobeNewswire
·
July 31, 2025
VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka …
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
GlobeNewswire
·
July 31, 2025
Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with …
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
July 31, 2025
Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring Deep Experience in Oncology Drug Development, Clinical …
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
GlobeNewswire
·
July 31, 2025
PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to …
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
GlobeNewswire
·
July 31, 2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial …
Kura Oncology to Report Second Quarter 2025 Financial Results
GlobeNewswire
·
July 31, 2025
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter …
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
GlobeNewswire
·
July 31, 2025
CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden regional availability over the next 12 months HOUSTON, …
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
GlobeNewswire
·
July 31, 2025
New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43 (P = 0.0035), ADCS-ADL difference: +9.50 (P < 0.0001) Restoring impaired autophagy as early event, …
Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
GlobeNewswire
·
July 31, 2025
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has …
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
GlobeNewswire
·
July 31, 2025
JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 …
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
GlobeNewswire
·
July 31, 2025
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and …
Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
GlobeNewswire
·
July 31, 2025
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use …
FOXO TECHNOLOGIES INC. ANNOUNCES LICENSE RENEWAL AND PROVIDES OPERATIONAL UPDATE FOR MYRTLE RECOVERY CENTERS, INC.
GlobeNewswire
·
July 31, 2025
WEST PALM BEACH, FLORIDA, July 31, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies, Inc., (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has renewed its operating license for …
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
July 31, 2025
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN Announced capped royalty purchase agreement with Sobi under which Apellis receives up to $300 million for 90% of ex-U.S. …
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
GlobeNewswire
·
July 31, 2025
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis …
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
GlobeNewswire
·
July 31, 2025
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on …
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
GlobeNewswire
·
July 31, 2025
CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today …
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
GlobeNewswire
·
July 31, 2025
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it …